Caribou Biosciences Inc. (CRBU)
Caribou Biosciences Statistics
Share Statistics
Caribou Biosciences has 90.55M shares outstanding. The number of shares has increased by 0.26% in one year.
| Shares Outstanding | 90.55M |
| Shares Change (YoY) | 0.26% |
| Shares Change (QoQ) | 0.21% |
| Owned by Institutions (%) | 57.9% |
| Shares Floating | 78.68M |
| Failed to Deliver (FTD) Shares | 1.15K |
| FTD / Avg. Volume | 0.08% |
Short Selling Information
The latest short interest is 10.8M, so 11.93% of the outstanding shares have been sold short.
| Short Interest | 10.8M |
| Short % of Shares Out | 11.93% |
| Short % of Float | 13.64% |
| Short Ratio (days to cover) | 6.76 |
Valuation Ratios
The PE ratio is -4.14 and the forward PE ratio is -0.67. Caribou Biosciences's PEG ratio is 0.26.
| PE Ratio | -4.14 |
| Forward PE | -0.67 |
| PS Ratio | 12.27 |
| Forward PS | 0.3 |
| PB Ratio | 1.15 |
| P/FCF Ratio | -4.03 |
| PEG Ratio | 0.26 |
Enterprise Valuation
Caribou Biosciences Inc. has an Enterprise Value (EV) of 399.24M.
| EV / Earnings | -3.91 |
| EV / Sales | 11.58 |
| EV / EBITDA | -3.55 |
| EV / EBIT | -3.44 |
| EV / FCF | -3.81 |
Financial Position
The company has a current ratio of 11.97, with a Debt / Equity ratio of 0.07.
| Current Ratio | 11.97 |
| Quick Ratio | 11.97 |
| Debt / Equity | 0.07 |
| Total Debt / Capitalization | 6.85 |
| Cash Flow / Debt | -3.44 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.28% and return on capital (ROIC) is -29.4%.
| Return on Equity (ROE) | -0.28% |
| Return on Assets (ROA) | -0.24% |
| Return on Capital (ROIC) | -29.4% |
| Revenue Per Employee | $218,208.86 |
| Profits Per Employee | $-646,012.66 |
| Employee Count | 158 |
| Asset Turnover | 0.08 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 193K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -84.98% in the last 52 weeks. The beta is 2.31, so Caribou Biosciences's price volatility has been higher than the market average.
| Beta | 2.31 |
| 52-Week Price Change | -84.98% |
| 50-Day Moving Average | 1.51 |
| 200-Day Moving Average | 1.98 |
| Relative Strength Index (RSI) | 31.82 |
| Average Volume (20 Days) | 1.39M |
Income Statement
In the last 12 months, Caribou Biosciences had revenue of 34.48M and earned -102.07M in profits. Earnings per share was -1.38.
| Revenue | 34.48M |
| Gross Profit | -77.6M |
| Operating Income | -116.06M |
| Net Income | -102.07M |
| EBITDA | -112.53M |
| EBIT | -116.06M |
| Earnings Per Share (EPS) | -1.38 |
Balance Sheet
The company has 51.16M in cash and 27.11M in debt, giving a net cash position of 24.05M.
| Cash & Cash Equivalents | 51.16M |
| Total Debt | 27.11M |
| Net Cash | 24.05M |
| Retained Earnings | -299.29M |
| Total Assets | 344.33M |
| Working Capital | 205.27M |
Cash Flow
In the last 12 months, operating cash flow was -93.29M and capital expenditures -11.61M, giving a free cash flow of -104.9M.
| Operating Cash Flow | -93.29M |
| Capital Expenditures | -11.61M |
| Free Cash Flow | -104.9M |
| FCF Per Share | -1.42 |
Margins
Gross margin is -225.07%, with operating and profit margins of -336.63% and -296.05%.
| Gross Margin | -225.07% |
| Operating Margin | -336.63% |
| Pretax Margin | -295.49% |
| Profit Margin | -296.05% |
| EBITDA Margin | -326.4% |
| EBIT Margin | -336.63% |
| FCF Margin | -304.27% |
Dividends & Yields
CRBU does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -117.95% |
| FCF Yield | -99.44% |
Analyst Forecast
The average price target for CRBU is $11, which is 840.2% higher than the current price. The consensus rating is "Buy".
| Price Target | $11 |
| Price Target Difference | 840.2% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
Scores
| Altman Z-Score | -1.49 |
| Piotroski F-Score | 2 |